gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · HBIOHealthcareLab Analytical Instruments

Harvard Bioscience Inc (HBIO)

$8.61−0.69%
Close Nov 4, 2026 · split-adjusted
Oct 30, 2026$8.90▲ 72.28% in range
Oct 31, 2025Low $4.31 · High $47.35Oct 30, 2026
What changed · written from our data
As of Nov 4, 2026

Harvard Bioscience closed at $8.61 on Nov 4, down 0.69%, 81.8% below its 52-week closing high. Volume of 10.2K shares was 0.62× its 20-day average (below normal).

Split-adjusted performance: +0.6% over one month, +18.9% over six months, +50.0% over one year.

In the quarter ended Jun 30, 2026, revenue was $22.73M, up 11.1% from a year earlier, with a net margin of -12.8%.

Short interest was 50.2K shares at the Oct 15 settlement, up 11.5% from the prior report (1.5% of float, 3.1 days to cover).

Market cap$39.2M4.6M shares
Revenue · quarter$22.7M+11.1% YoY
Diluted EPS$-0.64—
P/E · TTM—P/S 0.4×
Net margin-12.8%Gross 55.6%
Dividend yieldNone
52-week range4.31 – 47.35−81.8% from high
Volume10.2K0.62× 20-day avg
Volatility · 60d35.1%Annualised
Short % of float1.5%3.2 days to cover
Net cash-$30.2MCash $6.5M
Next earnings—Not scheduled
Split-adjusted performance
1W +2.3%1M +0.6%3M +39.1%6M +18.9%YTD +28.7%1Y +50.0%3Y −79.8%5Y −87.7%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Lab Analytical Instruments

Percentile among 22 companies (100 = best)

6-month momentum35
Revenue growth74
Net margin52
Value (low P/E)—
Size24

Industry medians: 6-month return +33.8%, revenue growth +4.9%, net margin −19.0%, P/E 38.3×.

Short interest

Details →
Shares short50.2K+11.5% vs prior
Days to cover3.2Settled Oct 15
% of float1.5%
Short vol. 10d37.0%of daily volume

Closest peers by size in Lab Analytical Instruments

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
HBIOHarvard Bioscience$8.61−0.69%+18.9%+11.1%−12.8%—$39.2M
PRPOPrecipio$19.57+5.10%−34.7%+24.7%−3.1%—$35.0MCompare
RPIDRapid Micro Biosystems$0.6814−1.53%−73.1%+10.9%−160.5%—$34.2MCompare
EYPTEyePoint$0.3950−1.23%−97.0%−90.5%−18633.1%—$34.1MCompare
BNGOBionano Genomics$1.19−0.83%−6.3%+21.4%−90.8%—$16.6MCompare
SEERSeer$1.70−1.73%−10.1%−23.4%−544.8%—$94.1MCompare
QTRXQuanterix$3.04+3.40%−7.6%+34.4%−148.7%—$143.8MCompare
ASTCAstrotech Corporation (DE)$4.51−7.20%+62.2%−42.7%−2592.1%—$9.5MCompare
NAUTNautilus Biotechnolgy$2.29−2.55%−22.1%—−6682.1%—$291.7MCompare

News about Harvard Bioscience

All news →

No recent articles focused on Harvard Bioscience. 1 articles mention it in passing.

Quick answers

What does Harvard Bioscience do?
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical.
What is HBIO's market cap?
$39.20M, based on the Nov 4 close of $8.61.
Does Harvard Bioscience pay a dividend?
No regular cash dividend has been paid in the last year.
How much of HBIO is sold short?
50.2K shares, 1.5% of float, as of Oct 15, 2026.
What sector is HBIO in?
Healthcare, in the Lab Analytical Instruments industry.

About Harvard Bioscience

Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.

HQ: Holliston, MA339 employeesListed Dec 7, 2000harvardbioscience.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology